Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

SRZN

+ Watchlist+ Portfolio

Surrozen, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$30.67
52-Week Range
$12.79 – $37.83
Market Cap
$596.41M
P/E (TTM)
—
EPS (TTM)
-38.95
Dividend Yield
0.00%
Advanced Metrics
Price/Book
—
PEG Ratio
—
Return on Equity
—
Return on Assets
-31.46%
Gross Margin
-257.52%
Operating Margin
-485.44%
Profit Margin
0.00%
Current Ratio
7.56
Debt/Equity
—
Total Debt
$5.84M
Free Cash Flow
$-14.76M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$447.98M

Market Snapshot

About

Surrozen, Inc. is a clinical-stage biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The companys antibody-based therapeutics target tissue-specific disease processes across multiple organs including the eye, liver, intestine, and kidney. It aims to address diseases where Wnt pathway dysregulation plays a critical role.